FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:457-463 July 31, 2003 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Perspective by Marini, J. C. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Bisphosphonates, synthetic analogues of inorganic pyrophosphate, potently inhibit skeletal resorption by suppressing the recruitment and activity of osteoclasts and shortening their life span.¹ Consequently, several bisphosphonates were developed to treat hypercalcemia (associated with cancer), osteoporosis, and Paget's disease of bone and are used for additional disorders in adults.¹ Increasingly, bisphosphonates are being administered to children^2,3,4 and have been reported to improve clinical outcomes and augment bone mass in conditions such as osteogenesis imperfecta,⁵ juvenile osteoporosis,² and fibrous dysplasia,⁶ although controlled studies of these compounds in children are lacking.^3,4,7 Genetic defects that abrogate the action of osteoclasts cause osteopetrosis, which is . . . [Full Text of this Article]

Case Report

Methods

Results

Discussion

Source Information

From the Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children (M.P.W., D.W., K.L.C., S.M.); the Division of Bone and Mineral Diseases, Washington University School of Medicine at Barnes–Jewish Hospital (M.P.W., S.M.); and Mallinckrodt Institute of Radiology, Washington University School of Medicine at St. Louis Children's Hospital (W.H.M.) — all in St. Louis.

Address reprint requests to Dr. Whyte at Shriners Hospitals for Children, 2001 S. Lindbergh Blvd., St. Louis, MO 63131-3597, or at mwhyte@shrinenet.org.

Related Letters:

Bisphosphonates in Children with Bone Diseases
Plotkin H., Glorieux F. H., Rauch F., Shapiro J. R., Bjarnason N. H., Whyte M. P., Wenkert D., McAlister W. H., Marini J. C.
Extract | Full Text | PDF  
N Engl J Med 2003; 349:2068-2071, Nov 20, 2003. Correspondence

This article has been cited by other articles:

• Bachrach, L. K., Ward, L. M. (2009). Clinical Review: Bisphosphonate Use in Childhood Osteoporosis. J. Clin. Endocrinol. Metab. 94: 400-409 [Abstract] [Full Text]  
• Henwood, M. J., Binkovitz, L. (2009). Update on Pediatric Bone Health. JAOA: Journal of the American Osteopathic Association 109: 5-12 [Abstract] [Full Text]  
• Weinstein, R. S., Roberson, P. K., Manolagas, S. C. (2009). Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy. NEJM 360: 53-62 [Abstract] [Full Text]  
• Shaw, N. J (2008). Management of osteoporosis in children. Eur J Endocrinol 159: S33-S39 [Abstract] [Full Text]  
• Visekruna, M., Wilson, D., McKiernan, F. E. (2008). Severely Suppressed Bone Turnover and Atypical Skeletal Fragility. J. Clin. Endocrinol. Metab. 93: 2948-2952 [Abstract] [Full Text]  
• Shaw, N J (2007). Osteoporosis in paediatrics. EDUCATION AND PRACTICE 92: 169-175 [Full Text]  
• Phal, P.M., Myall, R.W.T., Assael, L.A., Weissman, J.L. (2007). Imaging Findings of Bisphosphonate-Associated Osteonecrosis of the Jaws. Am. J. Neuroradiol. 28: 1139-1145 [Abstract] [Full Text]  
• Goh, S.-K., Yang, K. Y., Koh, J. S. B., Wong, M. K., Chua, S. Y., Chua, D. T. C., Howe, T. S. (2007). Subtrochanteric insufficiency fractures in patients on alendronate therapy: A CAUTION. J Bone Joint Surg Br 89-B: 349-353 [Abstract] [Full Text]  
• Klein, G. L., Bachrach, L. K., Holm, I. A. (2007). Effects of Pharmacologic Agents on Bone in Childhood: An Editorial Overview. Pediatrics 119: S125-S130 [Full Text]  
• Teitelbaum, S. L. (2007). Osteoclasts: What Do They Do and How Do They Do It?. Am. J. Pathol. 170: 427-435 [Abstract] [Full Text]  
• Watts, N. B., Harris, S. T., McClung, M. R., Bilezikian, J. P., Greenspan, S. L., Luckey, M. M. (2006). Bisphosphonates and osteonecrosis of the jaw.. ANN INTERN MED 145: 791-792 [Full Text]  
• Grigg, A. P., Shuttleworth, P., Reynolds, J., Schwarer, A. P., Szer, J., Bradstock, K., Hui, C., Herrmann, R., Ebeling, P. R. (2006). Pamidronate Reduces Bone Loss after Allogeneic Stem Cell Transplantation. J. Clin. Endocrinol. Metab. 91: 3835-3843 [Abstract] [Full Text]  
• Boyde, A. (2006). Jaw Bone Necrosis and Bisphosphonates: Microanatomical Questions. IBMS BoneKEy 3: 19-23 [Abstract] [Full Text]  
• Thornton, J, Ashcroft, D M, Mughal, M Z, Elliott, R A, O'Neill, T W, Symmons, D (2006). Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis. Arch. Dis. Child. 91: 753-761 [Abstract] [Full Text]  
• Tanvetyanon, T., Stiff, P. J. (2006). Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 17: 897-907 [Abstract] [Full Text]  
• Seeman, E., Delmas, P. D. (2006). Bone quality--the material and structural basis of bone strength and fragility.. NEJM 354: 2250-2261 [Full Text]  
• Woo, S.-B., Hellstein, J. W., Kalmar, J. R. (2006). Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws. ANN INTERN MED 144: 753-761 [Abstract] [Full Text]  
• Lasser, A. J. (2006). MORE ABOUT BON. Journal of the American Dental Association 137: 441-441 [Full Text]  
• Rauch, F., Travers, R., Glorieux, F. H. (2006). Pamidronate in Children with Osteogenesis Imperfecta: Histomorphometric Effects of Long-Term Therapy. J. Clin. Endocrinol. Metab. 91: 511-516 [Abstract] [Full Text]  
• MIGLIORATI, C. A., CASIGLIA, J., EPSTEIN, J., JACOBSEN, P. L., SIEGEL, M. A., WOO, S.-B. (2005). Managing the care of patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper. Journal of the American Dental Association 136: 1658-1668 [Abstract] [Full Text]  
• Morris, C. D., Einhorn, T. A. (2005). Bisphosphonates in Orthopaedic Surgery. JBJS 87: 1609-1618 [Abstract] [Full Text]  
• Shaw, N J, Bishop, N J (2005). Bisphosphonate treatment of bone disease. Arch. Dis. Child. 90: 494-499 [Abstract] [Full Text]  
• Teitelbaum, S. L. (2005). Osteoporosis and Integrins. J. Clin. Endocrinol. Metab. 90: 2466-2468 [Full Text]  
• Odvina, C. V., Zerwekh, J. E., Rao, D. S., Maalouf, N., Gottschalk, F. A., Pak, C. Y. C. (2005). Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy. J. Clin. Endocrinol. Metab. 90: 1294-1301 [Abstract] [Full Text]  
• Tanvetyanon, T. (2005). Re: Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Metastatic Hormone-Refractory Prostate Cancer. JNCI J Natl Cancer Inst 97: 70-70 [Full Text]  
• Tolar, J., Teitelbaum, S. L., Orchard, P. J. (2004). Osteopetrosis. NEJM 351: 2839-2849 [Full Text]  
• Marks, K. E., Crill, C. M. (2004). Calcium and Phosphorous in Pediatric Parenteral Nutrition. Journal of Pharmacy Practice 17: 432-446 [Abstract]  
• Cagle, A. P., Waguespack, S. G., Buckingham, B. A., Shankar, R. R., DiMeglio, L. A. (2004). Severe Infantile Hypercalcemia Associated With Williams Syndrome Successfully Treated With Intravenously Administered Pamidronate. Pediatrics 114: 1091-1095 [Abstract] [Full Text]  
• Kerrison, C., Davidson, J. E., Cleary, A. G., Beresford, M. W. (2004). Pamidronate in the treatment of childhood SAPHO syndrome. Rheumatology (Oxford) 43: 1246-1251 [Abstract] [Full Text]  
• Plotkin, H., Glorieux, F. H., Rauch, F., Shapiro, J. R., Bjarnason, N. H., Whyte, M. P., Wenkert, D., McAlister, W. H., Marini, J. C. (2003). Bisphosphonates in Children with Bone Diseases. NEJM 349: 2068-2071 [Full Text]